Should I buy or sell Quoin Pharmaceuticals stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Quoin Pharmaceuticals in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" QNRX shares. View QNRX analyst ratings or view top-rated stocks .

What is Quoin Pharmaceuticals' stock price target for 2024?

1 Wall Street research analysts have issued 12 month price targets for Quoin Pharmaceuticals' stock. Their QNRX share price targets range from $4.00 to $4.00. On average, they predict the company's share price to reach $4.00 in the next twelve months. This suggests a possible upside of 444.2% from the stock's current price. View analysts price targets for QNRX or view top-rated stocks among Wall Street analysts .

How have QNRX shares performed in 2024?

Quoin Pharmaceuticals' stock was trading at $4.91 at the start of the year. Since then, QNRX stock has decreased by 85.0% and is now trading at $0.7350. View the best growth stocks for 2024 here .

Are investors shorting Quoin Pharmaceuticals?

Quoin Pharmaceuticals saw a decrease in short interest during the month of March. As of March 31st, there was short interest totaling 11,600 shares, a decrease of 65.6% from the March 15th total of 33,700 shares. Based on an average daily trading volume, of 588,100 shares, the days-to-cover ratio is currently 0.0 days. View Quoin Pharmaceuticals' Short Interest .

When is Quoin Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024. View our QNRX earnings forecast .

How were Quoin Pharmaceuticals' earnings last quarter?

Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) posted its quarterly earnings results on Wednesday, March, 13th. The company reported ($2.08) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($2.37) by $0.29.

When did Quoin Pharmaceuticals' stock split?

Shares of Quoin Pharmaceuticals reverse split on Monday, July 17th 2023. The 1-12 reverse split was announced on Monday, July 17th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, July 17th 2023. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.

How do I buy shares of Quoin Pharmaceuticals?

Shares of QNRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:QNRX

Quoin Pharmaceuticals (QNRX) Stock Price, News & Analysis

→ REVEALED: Elon Musk’s Secret A.I. Facility? (From InvestorPlace) (Ad)

Free QNRX Stock Alerts

$0.74

-0.01 (-1.34%)

(As of 04/15/2024 ET)

Compare

Today's Range: $0.71
▼
$0.75
50-Day Range: $0.74
▼
$3.36
52-Week Range: $0.71
▼
$12.00

Volume: 81,502 shs
Average Volume: 535,871 shs
Market Capitalization: $2.71 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $4.00

Get Quoin Pharmaceuticals alerts:

Quoin Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 444.2% Upside
$4.00 Price Target
Short Interest: Healthy
0.31% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 1.44
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: N/A

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.59 out of 5 stars

3.5

Analyst's Opinion

Consensus Rating
Quoin Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Quoin Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
0.31% of the outstanding shares of Quoin Pharmaceuticals have been sold short.
Short Interest Ratio / Days to Cover
Quoin Pharmaceuticals has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Quoin Pharmaceuticals has recently decreased by 65.58%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Quoin Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Quoin Pharmaceuticals does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for QNRX.

3.0

News and Social Media Coverage

News Sentiment
Quoin Pharmaceuticals has a news sentiment score of 1.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.66 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Quoin Pharmaceuticals this week, compared to 0 articles on an average week.
Search Interest
Only 7 people have searched for QNRX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Quoin Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 3.30% of the stock of Quoin Pharmaceuticals is held by insiders.
Percentage Held by Institutions
Only 8.63% of the stock of Quoin Pharmaceuticals is held by institutions.

0.6

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Quoin Pharmaceuticals is -0.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Quoin Pharmaceuticals is -0.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Quoin Pharmaceuticals has a P/B Ratio of 0.13. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad InvestorPlace

A.I. “Perfect Storm” Could Send THESE Stocks Sky High

A little-known investment analyst whose performance beat out 15,000+ other experts in 2020 has identified an opportunity in the A.I. space. He's calling it A.I.'s perfect storm.

>>Check out what this A.I. Perfect Storm is<<

About Quoin Pharmaceuticals Stock (NASDAQ:QNRX)

Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma. It has a license agreement with Skinvisible Inc.; consulting agreements with Axella Research LLC; a Master Service Agreement with Therapeutics Inc.; and a research agreement with Queensland University of Technology. The company was founded in 2018 and is based in Ashburn, Virginia.

QNRX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

QNRX Stock News Headlines

March 16, 2024 | seekingalpha.com

Quoin Pharmaceuticals, Ltd. (QNRX) Q4 2023 Earnings Call Transcript

March 15, 2024 | markets.businessinsider.com

Maxim Group Maintains Buy Rating for Quoin Pharmaceuticals: Here's What You Need To Know

April 16, 2024 | InvestorPlace (Ad)

A.I. “Perfect Storm” Could Send THESE Stocks Sky High

A little-known investment analyst whose performance beat out 15,000+ other experts in 2020 has identified an opportunity in the A.I. space. He's calling it A.I.'s perfect storm.

March 15, 2024 | finance.yahoo.com

Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) Q4 2023 Earnings Call Transcript

March 14, 2024 | finanznachrichten.de

Quoin Pharmaceuticals, Inc.: Quoin Pharmaceuticals Provides Corporate Update and Announces Fourth Quarter and 2023 Financial Results

March 14, 2024 | benzinga.com

Quoin Pharmaceuticals: Q4 Earnings Insights

March 13, 2024 | globenewswire.com

Quoin Pharmaceuticals Provides Corporate Update and Announces Fourth Quarter and 2023 Financial Results

March 7, 2024 | msn.com

Why Quoin Pharmaceuticals (QNRX) Shares Are Nosediving

April 16, 2024 | InvestorPlace (Ad)

A.I. “Perfect Storm” Could Send THESE Stocks Sky High

A little-known investment analyst whose performance beat out 15,000+ other experts in 2020 has identified an opportunity in the A.I. space. He's calling it A.I.'s perfect storm.

March 7, 2024 | globenewswire.com

Quoin Pharmaceuticals Announces Fourth Quarter and 2023 Financial Results and Corporate Update Conference Call to be held on Thursday March 14th at 8:30 am ET

March 6, 2024 | finance.yahoo.com

QNRX: Potential Pool of Study Participants Expands; Financial Position Strengths

March 5, 2024 | seekingalpha.com

QTI, RNLX and MTC among pre-market losers

March 5, 2024 | msn.com

Why Is Quoin Pharmaceuticals (QNRX) Stock Down 50% Today?

March 5, 2024 | finance.yahoo.com

Quoin Pharmaceuticals Announces Pricing of $6.5 Million Public Offering

March 4, 2024 | marketwatch.com

Quoin Pharma Shares Double After FDA Grants Clearance for Teens in QRX003 Trial

March 4, 2024 | markets.businessinsider.com

Quoin Pharma Says FDA Clears Recruitment Of Teen Subjects For Two Ongoing Clinical Trials For QRX003

March 4, 2024 | msn.com

Why Quoin Pharmaceutical Stock Is Soaring

December 15, 2023 | markets.businessinsider.com

Buy Rating for Quoin Pharmaceuticals Amid Promising Netherton Syndrome Drug Prospects

December 13, 2023 | morningstar.com

Quoin Pharmaceuticals Ltd ADR

December 13, 2023 | finanznachrichten.de

Quoin Pharmaceuticals, Inc.: Quoin Pharmaceuticals Announces FDA Clearance of Clinical Optimization Plan for QRX003 for Netherton Syndrome

December 13, 2023 | markets.businessinsider.com

FDA Clears Quoin Pharma's Protocol Amendments For QRX003 Trials In Netherton Syndrome Treatment

November 13, 2023 | finance.yahoo.com

QNRX: Planned Protocol Modifications Might Accelerate QRX003 Regulatory Approval

November 10, 2023 | finance.yahoo.com

Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) Q3 2023 Earnings Call Transcript

November 10, 2023 | morningstar.com

Quoin Pharmaceuticals Ltd ADR QNRX

November 9, 2023 | msn.com

Quoin Pharmaceuticals GAAP EPS of -$7.61 misses by $4.89

November 8, 2023 | finance.yahoo.com

Quoin Pharmaceuticals Provides Corporate Update and Announces Third Quarter 2023 Financial Results

November 7, 2023 | benzinga.com

Preview: Quoin Pharmaceuticals's Earnings

See More Headlines

Receive QNRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Quoin Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/13/2024
Today: 4/15/2024
Next Earnings (Estimated): 5/13/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Surgical & medical instruments
Sub-Industry: N/A
Current Symbol: NASDAQ:QNRX
CUSIP: N/A
CIK: 1671502
Web: quoinpharma.com
Phone: (703) 980-4182
Fax: 972-9767-8750
Employees: 4
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $4.00
High Stock Price Target: $4.00
Low Stock Price Target: $4.00
Potential Upside/Downside: +444.2%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($10.2416)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-8,690,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -105.09%
Return on Assets: -55.69%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 3.15
Quick Ratio: 3.15

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $5.74 per share
Price / Book: 0.13

Miscellaneous

Outstanding Shares: 3,690,000
Free Float: 3,564,000
Market Cap: $2.71 million
Optionable: Not Optionable
Beta: 1.81

7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

Dr. Michael Myers Ph.D. (Age 62)
Co-Founder, CEO & Chairman
Comp: $661.8k
Ms. Denise Carter (Age 55)
Co-Founder, COO & Director
Comp: $537.8k
Mr. Gordon Bruce Dunn J.D. (Age 60)
Chief Financial Officer
Comp: $523.38k

Key Competitors

View All Competitors

QNRX Stock Analysis - Frequently Asked Questions

Should I buy or sell Quoin Pharmaceuticals stock right now?: 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Quoin Pharmaceuticals in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" QNRX shares.
View QNRX analyst ratings or view top-rated stocks.
What is Quoin Pharmaceuticals' stock price target for 2024?: 1 Wall Street research analysts have issued 12 month price targets for Quoin Pharmaceuticals' stock. Their QNRX share price targets range from $4.00 to $4.00. On average, they predict the company's share price to reach $4.00 in the next twelve months. This suggests a possible upside of 444.2% from the stock's current price.
View analysts price targets for QNRX or view top-rated stocks among Wall Street analysts.
How have QNRX shares performed in 2024?: Quoin Pharmaceuticals' stock was trading at $4.91 at the start of the year. Since then, QNRX stock has decreased by 85.0% and is now trading at $0.7350.
View the best growth stocks for 2024 here.
Are investors shorting Quoin Pharmaceuticals?: Quoin Pharmaceuticals saw a decrease in short interest during the month of March. As of March 31st, there was short interest totaling 11,600 shares, a decrease of 65.6% from the March 15th total of 33,700 shares. Based on an average daily trading volume, of 588,100 shares, the days-to-cover ratio is currently 0.0 days.
View Quoin Pharmaceuticals' Short Interest.

When is Quoin Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024.
View our QNRX earnings forecast.
How were Quoin Pharmaceuticals' earnings last quarter?: Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) posted its quarterly earnings results on Wednesday, March, 13th. The company reported ($2.08) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($2.37) by $0.29.
When did Quoin Pharmaceuticals' stock split?: Shares of Quoin Pharmaceuticals reverse split on Monday, July 17th 2023. The 1-12 reverse split was announced on Monday, July 17th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, July 17th 2023. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.
How do I buy shares of Quoin Pharmaceuticals?: Shares of QNRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:QNRX) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Quoin Pharmaceuticals (QNRX) Stock Price, News & Analysis

Quoin Pharmaceuticals MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

Company Ownership

Earnings and Valuation

About Quoin Pharmaceuticals Stock (NASDAQ:QNRX)

QNRX Stock Price History

QNRX Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

QNRX Stock Analysis - Frequently Asked Questions

Overall MarketRank^™